28 Primary and secondary liver malignancies

Primary and secondary liver malignancies

13

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/07/2022

TABLE 4 PUBLISHED LITERATURE OF SECONDARY LIVER LESIONS DIVIDED BY HISTOLOGY

Treated lesions (number)

Median overall survival (range)

D 100% (range)

Study (Year)

Lesion size (range)

Entity

Study design Patients (% male)

Local control

88.3% at 12 m 81.2% at 24 m 68% at 36 m

Colorectal carcinoma

Collettini (2014) [72] Ricke (2010) [71] Wieners (2009) [70] Collettini (2012) [68] Wieners (2011) [67] Schippers (2017) [76] Collettini (2011) [81] Omari (2019) [82] Omari (2019) [75] Heinze (2018) [66] (2012) [78]

Prospective, single-center 80 (75%) Prospective, single-center 73 (67.1%)

2.85 cm (0.8–10.7 cm) 3.6 cm (1–13.5 cm)

19.1 Gy (15–20 Gy)

179

18 m

3 dose groups 12.8–18.8 Gy 74.9% at 34 m

23.4m (26 m with CTX)

200

Prospective phase II, single-center

87% at 6 m 76% at 12 m 69% at 24 m

4.6 cm (1–12 cm)

3 dose groups 14.2–21.2 Gy

33 (56.3%)

138

n/a

Retrospective, single-center 37 (0%)

2.6 cm (0.8–7.4 cm) 4.4 cm (1.0–11 cm) 2.1 cm (0.7–11.0 cm) 3.1 cm (1.3-12 cm)

18.6 Gy (±2.27 Gy) 18.5 Gy (12–25 Gy) 15–20 Gy (target)

Breast cancer

80

94.6% at 12 m 18 m (3–39 m)

Prospective phase II, single-center

97% at 6 m 93.5% at 18 m 92% at 12 m 83% at 36 m 100% at avg. FU 15.4 m

41 (0%)

115

n/a

Neuroendocrine tumors

Retrospective, single-center 27 (48.1%) Retrospective, single-center 7 (0%) Retrospective, single-center 10 (70%) Retrospective, single-center 14 (64.3%) Retrospective, single-center 10 (90%) Retrospective, single-center 7 (28.5%) Retrospective, single-center 41 (55%) Retrospective, single-center 16 (62.5%)

36 m (4.2–106.1 m)

52

Ovarian cancer

12

15 Gy

100% at 12 m

Renal carcinoma Geisel

3.8 cm (1–8.2 cm)

93.8% at avg. FU 21.6 m ± 13.7 m) n/a

16

n/a

1.8 cm (0.5–13.9 cm) 16.1 Gy

92.6% avg. FU 10.2 (range 2.4–73.6 m)

51.2m (1.0–27.8 m) 37.3m (11.4–89.7 m) 25.2 m (6.5–51 m) 8.6 m (1.5–55.3m) 8.9 m (3.1-29.3 m)

54

Gastrointestinal stroma tumors

2.4 cm (0.6–11.2 cm) 1.2 cm (0.4–6.2 cm)

15 Gy (6.7–21.9 Gy)

97.5% at 25 m median FU

40

16.2 (12.0–32.6 Gy) 97.4% at 15 m

Anal cancer

38

Pancreas cancer Wieners

2.9 cm (1.0–7.3 cm) 18.1 Gy

49

91% at 12 m

(2015) [28]

Drewes (2019) [77]

2.2 cm (1.0-11.2 cm) A: 1.6 cm (0.4-3.8 cm) B: 6 cm (4-13.9 cm)

21 Gy (5-29.1 Gy)

87% at 3.3 m median FU

45

Heinze (2020) [83]

Retrospective, single-center 59 (71.1%)

17.1 Gy (5-29.1 Gy)

90.2% at 6m median FU n/a

Mixed

194

Kieszko (2018) [84] Ricke (2004)[85] Tselis (2013) [51] Walter (2021)[49] Geisel (2012b) [73] Omari (2019) [74]

Retrospective, single-center 61 (55.7%)

13 Gy (7-20 Gy) 17 Gy (12-25Gy)

88.7% at 6 m 70.7% at 12 m

96.7% at 6 m 79.6% at 12 m

73

<8 cm

Prospective phase II, single-center

7.7 cm (5.5-10.8 cm) 84 cm 3 (38-1348 cm 3 ) 3.2 cm (0.8-13.5 cm) 4.6 cm (1.4–6.8 cm) 2 cm (1–10.2 cm)

20 (55%)

20

93% at 12 m

n/a

Retrospective, single-center 41 (75%) Retrospective, single-center 106 (49%) Retrospective, single-center 8;(50%) Retrospective, single-center 12 (83.3%)

20 Gy (7-32 Gy) bid 19.3 Gy (7-27.9 Gy)

89% at 6 m 73% at 12 m 88.4% at 6 m 71.5% at 12 m 100% at 8.4 m (± 6.8 m FU)

13.2 m (0.6-31.8 m) 92.3% at 6 m 76.3% at 12 m

50

244

Gastric or gastroesophageal adenocarcinoma

21 Gy (5–29 Gy)

12

n/a

19.9 Gy (5.4–22.5 Gy)

89% at 8.3 m median FU

11.4 m (4.3–47 m)

36